Yvonne Saenger

Hematology | Oncology
1695 Eastchester Rd
Bronx, NY 10461

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 74 publications

The temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggests a window-of-opportunity for checkpoint inhibitor therapy in prostate cancer.

The temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggests a window-of-opportunity for checkpoint inhibitor therapy in prostate cancer.

Journal: medRxiv : the preprint server for health sciences
Published: February 06, 2026

A Conserved Landscape of Chemokine Receptor Co-expression Defines the Functional States of CD8+ T Cells in Melanoma.

A Conserved Landscape of Chemokine Receptor Co-expression Defines the Functional States of CD8+ T Cells in Melanoma.

Journal: bioRxiv : the preprint server for biology
Published: December 19, 2025

Synergistic Inhibition of Colorectal Cancer Growth by Combined PI3K and COX-2 Blockade in Cell Lines and Patient-Derived Organoids.

Synergistic Inhibition of Colorectal Cancer Growth by Combined PI3K and COX-2 Blockade in Cell Lines and Patient-Derived Organoids.

Journal: Pharmaceutics
Published: October 27, 2025

Correction: Nadelmann et al. Acral Melanoma in Skin of Color: Current Insights and Future Directions: A Narrative Review. Cancers 2025, 17, 468.

Correction: Nadelmann et al. Acral Melanoma in Skin of Color: Current Insights and Future Directions: A Narrative Review. Cancers 2025, 17, 468.

Journal: Cancers
Published: July 07, 2025

Pathologist-Read vs AI-Driven Assessment of Tumor-Infiltrating Lymphocytes in Melanoma.

Pathologist-Read vs AI-Driven Assessment of Tumor-Infiltrating Lymphocytes in Melanoma.

Journal: JAMA network open
Published: July 03, 2025

Case Report: An unexpected case of tumor regression in blue nevus melanoma following COVID-19 infection.

Case Report: An unexpected case of tumor regression in blue nevus melanoma following COVID-19 infection.

Journal: Frontiers in immunology
Published: July 02, 2025

Pathomic immune biomarkers define recurrence risk in early-stage melanoma.

Pathomic immune biomarkers define recurrence risk in early-stage melanoma.

Journal: The oncologist
Published: March 17, 2025

Acral Melanoma in Skin of Color: Current Insights and Future Directions: A Narrative Review.

Acral Melanoma in Skin of Color: Current Insights and Future Directions: A Narrative Review.

Journal: Cancers
Published: December 10, 2024

Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma.

Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 29, 2024

DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance.

DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance.

Journal: JCO precision oncology
Published: November 07, 2024

Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer.

Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer.

Journal: The oncologist
Published: April 12, 2024

First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.

First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.

Journal: Cancer research communications
Published: February 09, 2024
Showing 1-12 of 74

Last Updated: 09/26/2026